t
Several GSK plc Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) acquired Ordinary Shares or increased their notional interest in Ordinary Shares and American Depositary Shares (ADS) between July 9 and July 13, 2026. These transactions resulted from the re-investment of dividends, occurring on the London Stock Exchange or New York Stock Exchange, at prices ranging from £19.5950 to £19.7550 for Ordinary Shares and $52.4700 for ADSs.
| Date | 14 Jul 2026 |
| Time | 15:30:01 |
| Category | Director/PDMR dealings |
| ID | 3279M |
GSK plc (the 'Company')
Transaction notification
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Luke Miels |
|||
|
b) |
Position/status |
Chief Executive Officer |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.6297 |
20.727 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction)
|
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-07-09 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Lynn Baxter |
|||
|
b) |
Position/status |
President, Europe |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.6297 |
264.587 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-07-09 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mike Crichton |
|||
|
b) |
Position/status |
President, International |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.6297 |
113.059
|
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-07-09 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
James Ford |
|||
|
b) |
Position/status |
SVP and Group General Counsel, Legal and Compliance |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.6297 |
1,789.579
|
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-07-09 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Nina Mojas |
|||
|
b) |
Position/status |
President, Global Product Strategy |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.6297 |
218.712 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-07-09 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Roanne Parry |
|||
|
b) |
Position/status |
Chief People Officer |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.6297 |
1.244 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-07-09 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
David Redfern |
|||
|
b) |
Position/status |
President Corporate Development |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.6297 |
5,803.725
|
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-07-09 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Regis Simard |
|||
|
b) |
Position/status |
President, Global Supply Chain |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.6297 |
2,990.691
|
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-07-09 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Philip Thomson |
|||
|
b) |
Position/status |
President, Global Affairs |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.6297 |
2,405.345
|
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-07-09 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Deborah Waterhouse |
|||
|
b) |
Position/status |
CEO, ViiV Healthcare and President, Global Health, GSK |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.6297 |
1,070.064
|
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-07-09 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Tony Wood |
|||
|
b) |
Position/status |
Chief Scientific Officer |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.6297 |
2,273.327 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-07-09 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Neil Falkingham |
|||
|
b) |
Position/status |
PCA of Lynn Baxter (President, Europe) |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.6297 |
150.689
|
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-07-09 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Kate Thomson |
|||
|
b) |
Position/status |
PCA of Philip Thomson (President, Global Affairs) |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.6297 |
99.710 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-07-09 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
David Redfern |
|||
|
b) |
Position/status |
President Corporate Development |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.7550 |
6 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction)
|
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-07-13 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Neil Falkingham |
|||
|
b) |
Position/status |
PCA of Lynn Baxter (President, Europe) |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.7550 |
6 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction)
|
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-07-13 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Luke Miels |
|||
|
b) |
Position/status |
Chief Executive Officer |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.5950 |
664 |
|
||
|
|
£19.5950 |
333 |
|
||
|
|
£19.5950 |
244 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
1,241 £19.5950 |
||||
|
e) |
Date of the transaction |
2026-07-10 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Julie Brown |
|||
|
b) |
Position/status |
Chief Financial Officer |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.5950 |
533 |
|
||
|
|
£19.5950 |
621 |
|
||
|
|
£19.5950 |
482 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
1,636 £19.5950 |
||||
|
e) |
Date of the transaction |
2026-07-10 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
James Ford |
|||
|
b) |
Position/status |
SVP and Group General Counsel, Legal and Compliance |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.5950 |
115 |
|
||
|
|
£19.5950 |
357 |
|
||
|
|
£19.5950 |
216 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
688 £19.5950 |
||||
|
e) |
Date of the transaction |
2026-07-10 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Shobie Ramakrishnan |
|||
|
b) |
Position/status |
Chief Digital and Technology Officer |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADS')
ISIN: US37733W2044 |
|||
|
b) |
Nature of the transaction |
Increase in notional interest in ADS following the re-investment of dividends paid to shareholders on 9 July 2026 on ADSs held in the Company's Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
$52.4700 |
167 |
|
||
|
|
$52.4700 |
56 |
|
||
|
|
$52.4700 |
101 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
324 $52.4700 |
||||
|
e) |
Date of the transaction |
2026-07-10 |
|||
|
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
David Redfern |
|||
|
b) |
Position/status |
President, Corporate Development |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.5950 |
170 |
|
||
|
|
£19.5950 |
422 |
|
||
|
|
£19.5950 |
192 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
784 £19.5950 |
||||
|
e) |
Date of the transaction |
2026-07-10 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Regis Simard |
|||
|
b) |
Position/status |
President, Global Supply Chain |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.5950 |
178 |
|
||
|
|
£19.5950 |
282 |
|
||
|
|
£19.5950 |
509 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
969 £19.5950 |
||||
|
e) |
Date of the transaction |
2026-07-10 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Philip Thomson |
|||
|
b) |
Position/status |
President, Global Affairs |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.5950 |
123 |
|
||
|
|
£19.5950 |
284 |
|
||
|
|
£19.5950 |
171 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
578 £19.5950 |
||||
|
e) |
Date of the transaction |
2026-07-10 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Deborah Waterhouse |
|||
|
b) |
Position/status |
CEO, ViiV Healthcare and President, Global Health, GSK |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.5950 |
162 |
|
||
|
|
£19.5950 |
440 |
|
||
|
|
£19.5950 |
265 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
867 £19.5950 |
||||
|
e) |
Date of the transaction |
2026-07-10 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Tony Wood |
|||
|
b) |
Position/status |
Chief Scientific Officer |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s)
|
|
Price(s) |
Volume(s) |
|
|
|
£19.5950 |
247 |
|
||
|
|
£19.5950 |
542 |
|
||
|
|
£19.5950 |
226 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
1,015 £19.5950 |
||||
|
e) |
Date of the transaction |
2026-07-10 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
David Redfern |
|||
|
b) |
Position/status |
President Corporate Development |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on Ordinary Shares held within an ISA
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.755 |
18 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction)
|
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-07-13 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Victoria Whyte |
|||
|
b) |
Position/status |
SVP & Company Secretary |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on Ordinary Shares held within an ISA
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.755 |
15 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction)
|
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-07-13 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG